Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 30 µg injection once daily
LIXI_SC_30UG_QD
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 5 µg injection once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.54 (0.01 to 33.40) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.05 (0.63 to 6.44) | 0.37 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.51 (0.31 to 6.02) | 0.35 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.18 (0.00 to 3.82) | 0.85 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.05 (4.30 to 15.53) | 0.12 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 10.20 (3.86 to 29.54) | 0.13 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.83 (0.32 to 2.01) | 0.75 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.94 (0.05 to 15.67) | 0.45 |